增加对接受高排泄性化疗的患者的 olanzapine 处方
Ashley M Bowen1, Aimee Cloud2, Suzanne Fadly3
1Michigan Oncology Quality Consortium, Ann Arbor.
JAMA network open
|May 21, 2025
概括
在高排泄性化疗 (HEC) 抗排泄疗法中,olanzapine的使用通过质量改进计划显著增加. 这种合作努力使处方率从7.2%提高到63.4%,改善了患者的护理.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 提高质量 提高质量
背景情况:
- 奥兰沙平在高发性化疗 (HEC) 的4种药物抗发疗法中非常有效.
- 对于符合条件的HEC患者,全国 olanzapine 处方率仍然很低.
- 低处方率阻碍了最佳的化疗诱导的恶心和吐 (CINV) 预防.
研究的目的:
- 描述提高质量的努力,以增加HEC患者的指导方针一致的 olanzapine 使用.
- 评估全州瘤学协作倡议对奥兰扎处方的影响.
- 为了解决低的国家处方率的奥兰扎用于CINV预防.
主要方法:
- 全州范围内的瘤协作 (MOQC) 从2019-2023年实施了干预措施.
- 干预措施包括绩效审计,反,同行比较和学习协作.
- 还使用了面向患者的材料和基于价值的报销.
主要成果:
- 分析了38家诊所的8662名患者的数据.
- 奥兰沙平的使用量从2019年的7.2%增加到2024年的63.4% (P<.001).
- 在全州范围内观察到处方率的显著改善.
结论:
- 质量改进方法有效地增加了对HEC的 olanzapine 处方.
- 这些倡议在各种瘤实践中取得了成功.
- 这种方法可以改善患者护理和CINV预防.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
209
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
209
Psychosis: Goals of Pharmacotherapy
101
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
101
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
146
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
146
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
199
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
199
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140


